New Labour government backs pharma reform in UK
As the UK transitions into a Labour government, the pharma industry urges for boosted investment and talent attraction.
08 July 2024
08 July 2024
As the UK transitions into a Labour government, the pharma industry urges for boosted investment and talent attraction.
Approval is based on positive data from the Phase III FLAURA2 trial where Tagrisso plus chemotherapy showed PFS of 24.4 months.
Novo Holdings and Abingworth jointly spearheaded the investment round.
The development in Macau follows previous approvals on the Chinese mainland for the same indications.
While Regeneron and Sanofi secured approval in Europe for COPD, the FDA has delayed Dupixent’s application review for the disease in the US.
Used with chloroquine, tafenoquine can effectively treat both stages of the disease.
Fucaso, a BCMA CAR T-cell therapy, is co-developed by Innovent and IASO Bio and was approved to treat multiple myeloma in China last month.
XPOVIO met the pre-specified primary endpoint of the trial, with patients achieving a centrally assessed overall response rate.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional chronic kidney disease markets through 2033. Per our estimates, the sales of CKD therapeutics across the 7MM will grow at a CAGR of >19% between 2023 and 2033. The launch of eight oral pipeline agents and six injectable pipeline agents will be the main drivers of the CKD market across the 7MM.
Give your business an edge with our leading industry insights.